Market Overview

Cantor Fitzgerald Analyst Dr. Caroline Corner Says Cerus INTERCEPT Platelet Approval Means Company Can Approach Any Center, Will Be Able To Ramp Rev. With 80% Blood Centers Signed Up; Says This Is Built Into Her Numbers

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Latest Ratings for CERS

DateFirmActionFromTo
Apr 2016BTIG ResearchMaintainsBuy
Dec 2015WedbushDowngradesOutperformNeutral
Apr 2015BTIG ResearchInitiates Coverage onBuy

View More Analyst Ratings for CERS
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Guidance Exclusives Analyst Ratings General

 

Related Articles (CERS)